Confirmed Rheumatoid Arthritis
Diagnosis confirmed per ACR/EULAR 2010 criteria
All Pathways
RheumatologyManagement
Rheumatoid Arthritis Management (EULAR 2022)
Rheumatoid Arthritis Management (EULAR 2022): Confirmed Rheumatoid Arthritis → Overarching Principles → Poor Prognostic Factors? → Phase 1: csDMARD Ther...
Pathway Overview
15 steps
Algorithm Steps
15 total
01Start 02Action Overarching Principles
Key principles for RA management
- Treatment goal: remission or low disease activity
- Base decisions on disease activity, structural damage, comorbidities
- Shared decision-making with patient
- Rheumatologist should primarily manage RA
- Consider non-pharmacologic interventions (PT, OT)
03Decision Poor Prognostic Factors?
Assess for markers of severe/progressive disease
- High disease activity (DAS28, SDAI, CDAI)
- Positive RF and/or anti-CCP (especially high titers)
- Early erosions on imaging
- Elevated acute phase reactants (ESR, CRP)
- Failure of ≥2 csDMARDs
04Action Phase 1: csDMARD Therapy
Start conventional synthetic DMARD
- Methotrexate FIRST-LINE (if no contraindications)
- MTX dose: 15-25 mg/week (oral or SC)
- Add folic acid 5-10 mg/week
- If MTX contraindicated: leflunomide or sulfasalazine
- Short-term glucocorticoid bridging allowed
05Warning ⚠️ Glucocorticoid Bridging
Use with caution, taper within 3 months
- Consider when initiating/changing csDMARD
- Low-to-medium dose (≤7.5-10 mg pred equivalent)
- Taper to discontinue within 3 months
- Do NOT use as long-term monotherapy
06Decision Target Achieved at 3-6 Months?
Assess disease activity (DAS28, SDAI, or CDAI)
- Remission: DAS28 <2.6, SDAI ≤3.3, CDAI ≤2.8
- Low disease activity: DAS28 ≤3.2, SDAI ≤11, CDAI ≤10
- If improvement ≥50% at 3mo, may continue to 6mo
- If no improvement at 3mo, escalate
07Decision Sustained Remission?
Remission maintained for ≥6-12 months
08Action Consider Tapering
Cautious dose reduction in sustained remission
- First: taper glucocorticoids to zero
- Then: may taper b/tsDMARD (reduce dose or extend interval)
- Maintain csDMARD background therapy
- csDMARD tapering: only if very prolonged remission
- Monitor closely for flares
09Outcome RA Controlled
Remission or low disease activity achieved and maintained
10Warning Refractory RA
Failed multiple mechanisms - consider clinical trial, specialist center
11Action Phase 2: Add bDMARD or tsDMARD
After csDMARD failure (usually + MTX)
- bDMARDs: TNFi, IL-6i (tocilizumab, sarilumab), abatacept
- tsDMARDs: JAK inhibitors (tofacitinib, baricitinib, upadacitinib)
- Generally combine with MTX (or another csDMARD)
- TNFi biosimilars are preferred where available
12Warning ⚠️ JAKi Safety Considerations
Per ORAL Surveillance and regulatory guidance
- Increased CV events vs TNFi in high-risk patients
- Increased VTE risk
- Increased risk of malignancy in some populations
- Age ≥65, current/past smokers, CV risk: prefer bDMARD first
- If using JAKi: lowest effective dose
13Decision Target Achieved at 3-6 Months?
Reassess disease activity on b/tsDMARD
- Path rejoins step 07Shared downstream outcome
14Action Phase 3: Switch Mechanism
If first b/tsDMARD fails
- If TNFi fails: switch to different mechanism (IL-6i, abatacept, JAKi)
- If one mechanism fails: try different mechanism
- May try second TNFi if first failed for non-efficacy reason
- Rituximab: for seropositive RA after TNFi failure
15Action Rituximab (CD20 Inhibitor)
Especially for seropositive, refractory RA
- 1000mg IV x2 doses (days 0, 14)
- Repeat every 6-12 months based on activity
- Seropositive (RF+/CCP+) patients respond better
- Screen for hepatitis B/C before initiation
- Path rejoins step 07Shared downstream outcome
Guideline Source
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2022 update
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address juvenile idiopathic arthritis
- Biosimilar availability varies by region
- JAKi risk stratification requires individual assessment
- Drug interactions not comprehensively addressed
- Does not cover pregnancy-specific management (see separate guideline)
Contraindicated Populations
pediatric
Applicable Regions
EUUSAU
AU: ARA endorses EULAR recommendations
EU: EULAR 2022 is primary guidance
US: ACR 2021 also available - generally concordant
Version 1Next review: 2028-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Rheumatoid Arthritis Management (EULAR 2022)?
The Rheumatoid Arthritis Management (EULAR 2022) is a management clinical algorithm for Rheumatology. It provides a structured decision tree to guide clinical decision-making, based on EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2022 update.
What guideline is the Rheumatoid Arthritis Management (EULAR 2022) based on?
This algorithm is based on EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2022 update (DOI: 10.1136/ard-2022-223356).
What are the limitations of the Rheumatoid Arthritis Management (EULAR 2022)?
Known limitations include: Does not address juvenile idiopathic arthritis; Biosimilar availability varies by region; JAKi risk stratification requires individual assessment; Drug interactions not comprehensively addressed; Does not cover pregnancy-specific management (see separate guideline). Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Rheumatoid Arthritis Management (EULAR 2022) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free